Abstract
Introduction
This retrospective study aimed to characterize the clinical hematological and immunological features of patients with thymic epithelial neoplasms.
Methods
From a cohort of 512 patients with thymic epithelial neoplasms, 79 patients diagnosed with autoimmune/immunodeficiency conditions or signs and/or symptoms suggesting an autoimmune or immunodeficiency state were evaluated by standard immunological and hematological testing.
Results
Elevated percentages of CD2+, CD3+, and CD8+ lymphocytes were observed in 44 (57.1%), 33 (41.8%), and 32 (40.5%) patients. Low CD4+ and CD19+ percentages were observed in 25 (31.6%) and 36 (46.2%), respectively; CD4+:CD8+ ratios were inverted in 18 (22.8%). IgG, IgA, and IgM levels were low in 12 (15.8%), 9 (11.7%) and 15 (19.7%) patients, respectively. Patients with immunodeficiency condition(s) were more likely to have high CD8+ percentages (p = 0.040), low CD19+ percentages (p = 0.025), and/or inverted CD4+/CD8+ ratios (p = 0.034). Patients with autoimmune condition(s) were more likely to have a high/normal CD4+ percentage (p = 0.038). High CD2+ percentages were associated with lower mean IgG and IgA levels (p = 0.030 and p = 0.017, respectively). High CD3+ and CD8+ percentages were associated with lower mean IgA levels (p = 0.046 and p = 0.013, respectively). Low CD19+ percentages were associated with lower mean IgG and IgA levels (p = 0.004 and p < 0.001, respectively).
Conclusion
Signs/symptoms and history of autoimmune and immunodeficiency conditions among patients with thymic epithelial neoplasms are associated with high frequencies of abnormalities in immunoglobulin levels and lymphocyte immunophenotypes, suggesting a role for their assessment.
Similar content being viewed by others
References
Suster S, Moran CA. Thymoma, atypical thymoma, and thymic carcinoma. A novel conceptual approach to the classification of thymic epithelial neoplasms. Am J Clin Pathol. 1999;111:826–33.
Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: IARC; 2004.
Suster S, Moran CA. Histologic classification of thymoma: the World Health Organization and beyond. Hematol Oncol Clin N Am. 2008;22(3):381–92.
Masci AM, Palmieri G, Perna F, Montella L, Merkabaoui G, Sacerdoti G, et al. Immunological findings in thymoma and thymoma-related syndromes. Ann Med. 1999;31 Suppl 2:86–9.
Barnes EW, Irvine WJ. Clinical syndromes associated with thymic disorders. Proc R Soc Med. 1973;66:151–4.
Souadjian JV, Enriquez P, Silverstein MN, Pépin JM. The spectrum of diseases associated with thymoma. Coincidence or syndrome. Arch Intern Med. 1974;134:374–9.
Marx A, Schultz A, Wilisch A, Helmreich M, Nenninger R, Müller-Hermelink HK. Paraneoplastic autoimmunity in thymus tumors. Dev Immunol. 1998;6:129–40.
Evoli A, Minicuci GM, Vitaliani R, Battaglia A, Della Marca G, Lauriola L, et al. Paraneoplastic diseases associated with thymoma. J Neurol. 2007;254:756–62.
Nelson Jr RP, Pascuzzi RM. Paraneoplastic syndromes in thymoma: an immunological perspective. Curr Treat Options Oncol. 2008;9:269–76.
Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin N Am. 2008;8:509–26.
Rosenow EC, Hurley BT. Disorders of the thymus. A review. Arch Intern Med. 1984;144:763–70.
Kelesidis T, Yang O. Good's syndrome remains a mystery after 55 years: a systematic review of the scientific evidence. Clin Immunol. 2010;135:347–63.
Castro KG, Ward JW, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL, et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1–19.
Jones JL, Hanson DL, Dworkin MS, Alderton DL, Fleming PL, Kaplan JE, et al. Surveillance for AIDS-defining opportunistic illnesses, 1992–1997. MMWR CDC Surveill Summ. 1999;48(2):1–22.
Baker CJ, Kasper DL, Edwards MS, Schiffman G. Influence of preimmunization antibody levels on the specificity of the immune response to related polysaccharide antigens. N Engl J Med. 1980;303(4):173–8.
Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003;105(4):546–51.
Salyer WR, Eggleston JC. Thymoma: a clinical and pathological study of 65 cases. Cancer. 1976;37(1):229–49.
Rubin M, Straus B, Allen L. Clinical disorders associated with thymic tumors. Arch Intern Med. 1964;114:389–98.
Ammus SS, Yunis AA. Acquired pure red cell aplasia. Am J Hematol. 1987;24(3):311–26.
Yip D, Rasko JE, Lee C, Kronenberg H, O'Neill B. Thymoma and agranulocytosis: two case reports and literature review. Br J Haematol. 1996;95(1):52–6.
Kelleher P, Misbah SA. What is Good's syndrome? Immunological abnormalities in patients with thymoma. J Clin Pathol. 2003;56(1):12–6.
Tarr PE, Sneller MC, Mechanic LJ, Economides A, Eger CM, Strober W, et al. Infections in patients with immunodeficiency with thymoma (Good syndrome). Report of 5 cases and review of the literature. Medicine (Baltimore). 2001;80(2):123–33.
Miyakis S, Pefanis A, Passam FH, Christodulakis GR, Roussou PA, Mountokalakis TD. Thymoma with immunodeficiency (Good's syndrome): review of the literature apropos three cases. Scand J Infect Dis. 2006;38(4):314–9.
Di Renzo M, Pasqui A, Bruni F, Voltolini L, Rottoli P, Perali G, et al. Thymoma and immunodeficiency. N Z Med J. 2004;117(1188):U750.
Vitiello L, Masci AM, Montella L, Perna F, Angelini DF, Borsellino G, et al. Thymoma-associated immunodeficiency: a syndrome characterized by severe alterations in NK, T and B-cells and progressive increase in naive CD8+ T cells. Int J Immunopathol Pharmacol. 2010;23(1):307–16.
Tarr PE, Lucey DR. Good's syndrome: the association of thymoma with immunodeficiency. Clin Infect Dis. 2001;33(4):585–6.
Del Pozo N, Sarmiento E, Lanio N, Gallego A, Largo J, Carbone J. Immunophenotypic abnormalities of CD8+ T-cell subsets in a patient with unusual Good's syndrome. Allergol Immunopathol (Madr). 2010;38(2):102–5.
Baumert E, Schlesier M, Wolff-Vorbeck G, Peter HH. Alterations in lymphocyte subsets in variable immunodeficiency syndrome. Immun Infekt. 1992;20(3):73–5.
Hanafusa T, Umegaki N, Yamaguchi Y, Katayama I. Good’s syndrome (hypogammaglobulinemia with thymoma) presenting intractable opportunistic infections and hyperkeratotic lichen planus. J Dermatol. 2010;37(2):171–4.
Jaffe JS, Eisenstein E, Sneller MC, Strober W. T-cell abnormalities in common variable immunodeficiency. Pediatr Res. 1993;33 Suppl 1:24–7.
Burbelo PD, Browne SK, Sampaio EP, Giaccone G, Zaman R, Kristosturyan E, et al. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood. 2010;116(23):4848–58.
Nagvekar N, Moody AM, Moss P, Roxanis I, Curnow J, Beeson D, et al. A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest. 1998;101:2268–77.
Okereke IC, Kesler KA, Morad MH, Mi D, Rieger KM, Birdas TJ, et al. Prognostic indicators after surgery for thymoma. Ann Thorac Surg. 2010;89(4):1071–9.
Mateo-Montoya A, Stanescu D, Wolff B, Sahel JA, Bonnel S. Cytomegalovirus retinitis associated with Good's syndrome. Eur J Ophthalmol. 2010;20(2):479–80.
Squintani G, Ferrari S, Bazzoli E, Eleopra R, La Monaca C, Cagliari E, et al. Progressive multifocal leukoencephalopathy in a patient with Good's syndrome. Int J Infect Dis. 2010;14(5):e444–7.
Kuribayashi K, Fujimi A, Kobune M, Takimoto R, Kikuchi S, Iyama S, et al. Pure red cell aplasia associated with Good's syndrome accompanied by decreased stem cell factor production in the bone marrow. Intern Med. 2010;49(5):377–82.
Marx A, Hohenberger P, Hoffmann H, Pfannschmidt J, Schnabel P, Hofmann HS, et al. The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond. J Thorac Oncol. 2010;5(10 Suppl 4):S266–72.
Ströbel P, Helmreich M, Menioudakis G, Lewin SR, Rüdiger T, Bauer A, et al. Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. Blood. 2002;100(1):159–66.
Ströbel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol. 2004;22(8):1501–9.
Ströbel P, Murumägi A, Klein R, Luster M, Lahti M, Krohn K, et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol. 2007;211(5):563–71.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khawaja, M.R., Nelson, R.P., Miller, N. et al. Immune-Mediated Diseases and Immunodeficiencies Associated with Thymic Epithelial Neoplasms. J Clin Immunol 32, 430–437 (2012). https://doi.org/10.1007/s10875-011-9644-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-011-9644-1